Introduction
Cystic fibrosis (CF),' a chronic disorder caused by mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene, has its major clinical manifestations in the lung, with accumulation ofpurulent mucus, bacterial infections, and airway inflammation and obstruction leading to respiratory failure and death usually by the third decade (1) (2) (3) (4) . The exact mechanisms by which mutations of the CFTR gene result in these respiratory manifestations are not clear, but it is recognized that epithelial inflammation dominated by neutrophils plays a major role in the respiratory derangements associated with this disease (4) (5) (6) . Although the neutrophils that accumu-late on the airway epithelial surface may act appropriately and help in the clearance ofmicroorganisms, they also have a deleterious effect on the epithelium itself (7-1 1 ). To a large extent, this damage is mediated by neutrophil elastase (NE), a proteolytic enzyme which directly damages epithelial cells, and interferes with normal host defense (5, 7, (9) (10) (11) (12) (13) (14) . Although the lung normally has sufficient amounts of serine antiproteases on the epithelial surface to protect against NE, the burden of neutrophils and hence NE is so great in CF that the serine antiprotease defensive shield is overwhelmed (5, 6, 15, 16) .
The mechanisms by which neutrophils are attracted to the epithelial surface in CF are complex, and likely involve a variety of neutrophil chemoattractants generated in the airways (17, 18) . One neutrophil chemoattractant, interleukin 8 (IL-8), may play a significant role in this process. IL-8, an 8.5-kD protein with potent neutrophil chemoattractive and activating properties, can be produced by bronchial epithelial cells after exposure to a variety of inflammatory mediators (19) (20) (21) (22) (23) pM) and highly specific (no detectable cross-reactivity with recombinant human interleukin-l (IL-l), IL-2, IL-4, IL-6, interferon-y, tumor necrosis factor-a, or granulocyte monocyte colony-stimulating factor). The amount of active NE in ELF was determined using the NE-specific substrate methoxy-succinyl-alanyl-alanyl-prolyl-valyl-nitroanilide in comparison to a NE standard ofknown activity (28) . The levels ofSLPI in ELF were quantified using a double-sandwich ELISA (29) . The volume of ELF was measured by the urea method (27) . NE activity, SLPI, and ELF measures were all performed in triplicate and the mean determined.
In vivo administration ofrecombinant SLPI (rSLPI). rSLPI (Synergen, Boulder, CO) is a 12-kD single-chain nonglycosylated protein identical in structure and function as an inhibitor of NE to normal human SLPI (30) . rSLPI, produced in Escherichia coli transformed with an SLPI expression vector as previously described (31 ) , retains its structure and function when aerosolized in vitro or to experimental animals (32).
Aerosolization of rSLPI to individuals with CF was carried out in two phases: an initial dose escalation study to evaluate safety and to provide an initial estimate of in vivo pharmacokinetics, followed by a l-wk study with a fixed dose for 7 d. Two individuals participated in both phases with an interval of > 1 mo between the two phases. The aerosol was generated with a compressed air-driven nebulizer (32). In vitro studies demonstrated the generated aerosol had a mass median diameter of 2.8 Mm, similar to the characteristics ofthe aerosol used to deliver rSLPI to the respiratory epithelial surface oflarge animals (32). For the initial dose escalating study, five individuals with CF received rSLPI at an escalating once daily dose of 1, 12.5, 25, 50, and 100 mg, immediately followed by a twice daily dose of 100 mg for 2 d. All were evaluated by bronchoalveolar lavage before therapy and 12 h after the last aerosol. For the l-wk study 17 individuals with CF received an aerosol of rSLPI at a dose of 100 mg twice daily for 7 d and were evaluated by lavage pretherapy and at 4 h (n = 8) or 12 h (n = 8) after their 13th and 14th aerosol, respectively. One individual was removed from protocol because of inability to use the nebulizer device secondary to a preexisting debilitating extrapyramidal tremor; these results are not included. probe generated by the random priming method, and autoradiography (23, 37, 38) . The IL-8 cDNA probe was constructed using polymerase chain reaction amplification ofRNA (after conversion to cDNA) from lipopolysaccharide-stimulated human blood monocytes (23 Fig. 2 B) i.e., despite the presence of SLPI, the burden ofNE is so great in CF ELF that it far overweighs the anti-NE defenses, permitting active NE to be present in ELF. Aerosol therapy with rSLPI was well tolerated, patients taking -25 min to inhale a complete 100-mg dose of rSLPI. The initial study with an escalating dose of rSLPI suggested that a dose of 100 mg every 12 h would significantly raise ELF SLPI levels and suppress ELF active NE levels. After aerosolization of rSLPI, ELF levels ofSLPI increased significantly, compared to pretherapy levels (P < 0.01 ) (Fig. 2 A) . Western blot analysis of ELF pretherapy showed SLPI in a cleaved or complexed form, but after aerosolization of rSLPI, normal molecular size SLPI was now evident in ELF (not shown). The augmentation (Fig. 4) . In this regard, for 15 of 21 CF individuals receiving the rSLPI aerosol, ELF IL-8 levels decreased; for the group as a whole there was a 50% reduction in ELF IL-8 levels (before therapy 21.7±4.8 nM, after therapy 10.7±1.4 nM; P < 0.05). Concomitant with this was a fall in the number of neutrophils in ELF ( Fig. 5 ; before therapy 10.6±1.8 X 104/ L of ELF, after therapy 5.8±0.8 X 104/,uL ofELF; P < 0.02). Further, as evidence that NE in CF ELF induced IL-8 gene expression in vivo, the relationship of ELF IL-8 and active NE in CF ELF (all data combined, including before and after therapy) demonstrated a remarkable correlation (r = 0.94, P < 0.01; Fig. 6 (Fig. 2 B) . In this regard, for 18 of21 individuals, there was a significant suppression ofELF NE. For the entire group, the pretherapy active NE levels decreased an average of 68% (P < 0.03).
In the context that NE was present on the CF respiratory epithelial surface, and that NE in CF ELF is capable of inducing bronchial epithelial cells to express the IL-8 gene (24) The major clinical manifestations of CF take place on the respiratory epithelial surface (4-6). Although neutrophils in the lung in CF must have a protective value in regards to host defense, the massive chronic neutrophil-dominated inflammatory response in CF is associated with chronic epithelial damage (4-1 1). There is growing evidence that NE released by the neutrophils plays a major role in this process, not only by its direct assault on the respiratory epithelial surface but also by impairing lung defense by virtue ofits ability to adversely affect mucociliary clearance, and to cleave immunoglobulins, complement components, and complement receptors on neutrophils (9) (10) (11) (12) (13) (14) 39) . The later observation is of particular importance for respiratory host defense, in that many of the neutrophils attracted to the CF lung may be rendered ineffective and thus may cause damage rather than provide antimicrobial protection (5, 12, 13 (44, 45) . Further, rSLPI has an isoelectric point similar to that of LI. 
